Top 50 Pharma companies
The top 50 pharma companies by sales — reports from 2008 and 2009:
Abbott, Actavis, Alcon, Allergan, Amgen, Astellas, AstraZeneca, Barr
Pharmaceuticals, Baxter, Bayer, Biogen Idec, Boehringer-Ingelheim,
Bristol-Myers Squibb, Chugai, CSL, Daiichi Sankyo, Eisai, Eli Lilly,
Forest, Genentech, Genzyme, Gilead Sciences,GlaxoSmithKline Johnson &
Johnson, King Pharmaceuticals, Lundbeck, Menarini, Merck , Merck KGaA,
Mitsubishi Tanabe, Mundipharma, Novartis, Novo Nordisk, Nycomed, Otsuka,
P&G, Pfizer, Ratiopharm, Roche, Sanofi-Aventis, Schering-Plough, Servier,
Shire, Solvay, Stada, Takeda,Teva UCB, Watson and Wyeth.
Click on a report title below to see details of contents and dollar
and euro prices.
| Title |
Publication Date |
Price |
Abbott Laboratories: PharmaVitae Model
|
January 2009 |
£3010 |
Abbott Laboratories: PharmaVitae Profile
Healthcare
|
March 2009 |
£3010 |
Alcon Inc.: PharmaVitae Model
|
January 2009 |
£3010 |
Allergan IMS Company Profile
|
June 2008 |
£510 |
Allergan Inc.: PharmaVitae Model
|
January 2009 |
£3010 |
Allergan: Pipeline , Products , Performance , Potential
|
February 2008 |
£595 |
Amgen IMS Company Profile
|
October 2008 |
£510 |
Amgen Inc.: PharmaVitae Model
|
January 2009 |
£3010 |
Amgen Inc.: PharmaVitae Profile
Healthcare
|
March 2009 |
£3010 |
Astellas
|
July 2008 |
£510 |
Astellas Pharma Inc.: PharmaVitae Model
|
January 2009 |
£3010 |
Astellas Pharma Inc.: PharmaVitae Profile
|
February 2009 |
£3010 |
AstraZeneca
Pharmaceuticals, Company Profile and Healthcare
|
June 2008 |
£595 |
AstraZeneca IMS Company Profile
|
November 2008 |
£510 |
AstraZeneca Plc
PharmaVitae Profile
|
July 2008 |
£3010 |
AstraZeneca plc: PharmaVitae Model
|
January 2009 |
£3010 |
Bayer
Pipeline, Products ,Performance ,Potential
|
September 2008 |
£595 |
Bayer IMS Company Profile
|
October 2008 |
£510 |
Bayer Schering Pharma AG: PharmaVitae Model
|
January 2009 |
£3010 |
Bayer Schering Pharma Ag
PharmaVitae Profile
|
July 2008 |
£3010 |
Biogen Idec IMS Company Profile
|
October 2008 |
£510 |
Biogen Idec Inc.: PharmaVitae Model
|
January 2009 |
£3010 |
Boehringer Ingelheim
|
July 2008 |
£510 |
Boehringer Ingelheim
Pipeline ,Products ,Performance ,Potential
|
November 2008 |
£595 |
Boehringer Ingelheim IMS Company Profile
|
November 2008 |
£510 |
Boehringer Ingelhgeim GmbH: PharmaVitae Model
|
January 2009 |
£3010 |
Bristol-Myers Squibb
Pipeline, Products, Performance, Potential
|
February 2008 |
£595 |
Bristol-Myers Squibb Co.: PharmaVitae Model
|
January 2009 |
£3010 |
Bristol-Myers Squibb IMS Company Profile
|
November 2008 |
£510 |
Byetta Case Study
Using Medical Education as a Springboard for Product Launch
|
August 2008 |
£2885 |
Chugai IMS Company Profile
|
May 2008 |
£510 |
Chugai Pharmaceutical Co. Ltd: PharmaVitae Model
|
January 2009 |
£3010 |
Cymbalta Case Study
Successfully Entering a Crowded Market with a New Mechanism of Action
|
June 2008 |
£3170 |
Daiichi Sankyo
|
July 2008 |
£510 |
Daiichi Sankyo Co., Ltd: PharmaVitae Model
|
January 2009 |
£3010 |
Daiichi Sankyo Co., Ltd: PharmaVitae Profile
|
February 2009 |
£3010 |
Eisai
|
July 2008 |
£510 |
Eisai Co. Ltd: PharmaVitae Model
|
January 2009 |
£3010 |
Eli Lilly & Co.: PharmaVitae Model
|
January 2009 |
£3010 |
Exubera Case Study
Misjudging The Market
|
July 2008 |
£1760 |
Flomax Case Study
Evolving Disease State Awareness to Succeed with New Method of Action
|
July 2008 |
£2110 |
Forest Laboratories Inc.: PharmaVitae Model
|
January 2009 |
£3010 |
Forest Laboratories Inc.: PharmaVitae Profile
|
November 2008 |
£3010 |
Genentech Inc.: PharmaVitae Model
|
January 2009 |
£3010 |
Genzyme Corporation: PharmaVitae Model
|
January 2009 |
£3010 |
Gilead Sciences IMS Company Profile
|
June 2008 |
£510 |
Gilead Sciences Inc.: PharmaVitae Model
|
January 2009 |
£3010 |
Johnson & Johnson
PharmaVitae Profile
|
July 2008 |
£3010 |
Johnson & Johnson IMS Company Profile
|
October 2008 |
£510 |
Johnson & Johnson: PharmaVitae Model
|
January 2009 |
£3010 |
Johnson & Johnson: PharmaVitae Profile
Healthcare
|
March 2009 |
£3010 |
Johnson & Johnson: Strategic Analysis Profile
|
February 2008 |
£515 |
King Pharmaceuticals IMS Company Profile
|
October 2008 |
£510 |
King Pharmaceuticals Inc.: PharmaVitae Model
|
January 2009 |
£3010 |
Les Laboratoires Servier: PharmaVitae Model
|
January 2009 |
£3010 |
Lundbeck IMS Company Profile
|
November 2008 |
£510 |
Merck & Co IMS Company Profile
|
October 2008 |
£510 |
Merck & Co. Inc: PharmaVitae Model
|
January 2009 |
£3010 |
Merck KGaA
Pipeline ,Products ,Performance ,Potential
|
September 2008 |
£595 |
Merck KGaA: PharmaVitae Model
|
January 2009 |
£3010 |
Mitsubishi Tanabe Pharma Corporation: PharmaVitae Model
|
January 2009 |
£3010 |
Mylan Generics Company Intelligence Report
Company Intelligence Report
|
June 2008 |
£195 |
Mylan IMS Company Profile
|
June 2008 |
£510 |
Nexium Case Study: Using Public Relations to Reach Diverse Patient Populations and Build Bridges Between Product Generations
|
October 2008 |
£995 |
Novartis
Pipeline ,Products ,Performance ,Potential
|
August 2008 |
£595 |
Novartis AG: PharmaVitae Model
|
January 2009 |
£3010 |
Novo Nordisk A/S: PharmaVitae Model
|
January 2009 |
£3010 |
Pfizer
Pipeline ,Products ,Performance ,Potential
|
June 2008 |
£595 |
Pfizer
Market Outlook for a Global Leader, 2008-2013
|
August 2008 |
£1499 |
Pfizer
IMS Company Profile
|
July 2008 |
£510 |
Pfizer IMS Company Profile
|
October 2008 |
£510 |
Pfizer Inc.: PharmaVitae Model
|
January 2009 |
£3010 |
Roche IMS Company Profile
|
October 2008 |
£510 |
SERVIER -Company Report
|
February 2008 |
£375 |
Sanofi-Aventis: PharmaVitae Model
|
January 2009 |
£3010 |
Schering-Plough
Pipeline ,Products ,Performance ,Potential
|
August 2008 |
£595 |
Schering-Plough Corporation
PharmaVitae Profile
|
July 2008 |
£3010 |
Schering-Plough Corporation: PharmaVitae Model
|
January 2009 |
£3010 |
ScientiaVision Competitor Close-up: Merck & Company, Inc.
|
December 2008 |
£520 |
Shionogi & Co. Ltd: PharmaVitae Model
|
January 2009 |
£3010 |
Shire
|
July 2008 |
£510 |
Shire plc: PharmaVitae Model
|
January 2009 |
£3010 |
Shire plc: PharmaVitae Profile
|
November 2008 |
£3010 |
Shire: Pipeline | Products | Performance | Potential
|
May 2008 |
£595 |
Slentrol Case Study: Using Integrated PR Tactics to Support a Product Launch
|
October 2008 |
£665 |
Solvay IMS Company Profile
|
May 2008 |
£510 |
Solvay S.A.: PharmaVitae Model
|
January 2009 |
£3010 |
Takeda IMS Company Profile
|
June 2008 |
£510 |
Takeda Pharmaceutical Co. Ltd: PharmaVitae Model
|
January 2009 |
£3010 |
Teva Generics Company Intelligence Report
Company Intelligence Report
|
June 2008 |
£195 |
Teva IMS Company Profile
|
November 2008 |
£510 |
Teva Pharmaceutical Industries Ltd: PharmaVitae Model
|
January 2009 |
£3010 |
UCB IMS Company Profile
|
May 2008 |
£510 |
Watson IMS Company Profile
|
November 2008 |
£510 |
Watson Pharmaceuticals Generics Company Intelligence Report
Company Intelligence Report
|
June 2008 |
£195 |
Watson Pharmaceuticals Inc.: PharmaVitae Model
|
January 2009 |
£3010 |
Wyeth
PharmaVitae Profile
|
July 2008 |
£3010 |
Wyeth IMS Company Profile
|
November 2008 |
£510 |
Wyeth: PharmaVitae Model
|
January 2009 |
£3010 |
Zimmer Medical Device Company Intelligence Report
|
December 2008 |
£395 |
To top
|
|
|